<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0002169'>Wild-type</z:mp> human p53 and a series of p53 point mutants isolated from Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cell lines were tested for their ability to inhibit DNA synthesis in a p53-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell line and to bind and be degraded by the <z:e sem="disease" ids="C0850011,C0850009" disease_type="Disease or Syndrome" abbrv="">human papillomavirus</z:e> type 16 E6 protein </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the mutants lost the <z:mp ids='MP_0002169'>wild-type</z:mp> ability to inhibit DNA synthesis, demonstrating that they are <z:hpo ids='HP_0000001'>all</z:hpo> functionally altered </plain></SENT>
<SENT sid="2" pm="."><plain>Binding to E6 and consequent degradation of the p53 mutants frequently correlated with changed suppressor properties in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells </plain></SENT>
</text></document>